SG Americas Securities LLC Invests $76,000 in biote Corp. (NASDAQ:BTMD)

SG Americas Securities LLC acquired a new stake in shares of biote Corp. (NASDAQ:BTMD) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,238 shares of the company’s stock, valued at approximately $76,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Jane Street Group LLC lifted its holdings in biote by 24.7% during the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock valued at $94,000 after buying an additional 3,342 shares in the last quarter. MetLife Investment Management LLC grew its position in shares of biote by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after buying an additional 9,343 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of biote in the 2nd quarter worth approximately $84,000. Quarry LP purchased a new position in shares of biote in the 3rd quarter worth approximately $104,000. Finally, Victory Capital Management Inc. purchased a new stake in biote during the 3rd quarter worth approximately $106,000. Institutional investors own 21.68% of the company’s stock.

biote Trading Down 1.7 %

Shares of NASDAQ BTMD opened at $4.58 on Friday. biote Corp. has a 12 month low of $4.40 and a 12 month high of $8.44. The company has a 50 day simple moving average of $5.80 and a two-hundred day simple moving average of $5.88. The stock has a market cap of $248.86 million, a price-to-earnings ratio of 17.62 and a beta of 1.04.

Wall Street Analyst Weigh In

Separately, Craig Hallum began coverage on shares of biote in a research report on Monday, December 16th. They set a “buy” rating and a $12.00 target price on the stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.